Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 15/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948665 | 0.84 | HRH3 (0.47) | ADORA1ADORA2AHRH3ADORA2B | |
| SCHEMBL2953623 | 0.73 | TNK2 (0.57) | HRH3 | |
| SCHEMBL2959696 | 0.72 | TNK2 (0.58) | — | |
| SCHEMBL11846475 | 0.70 | HSD17B10 (0.60) | HRH3SIGMAR1 | |
| SCHEMBL10832093 | 0.70 | BCHE (0.46) | HRH3SIGMAR1 | |
| SCHEMBL10368142 | 0.70 | BCHE (0.46) | HRH3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL11834393 | 0.69 | HSD17B10 (0.59) | HRH3SIGMAR1 | |
| SCHEMBL2951939 | 0.69 | SRC (0.57) | ADORA1ADORA2AADORA3 | |
| SCHEMBL10369845 | 0.68 | BCHE (0.45) | HRH3DRD3 | |
| SCHEMBL8129925 | 0.67 | PIK3CD (0.50) | ADORA1ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | ADORA1 3200/4885ADORA2A 3626/4885HRH3 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.